SG11201909062WA - Pharmaceutical formulation - Google Patents
Pharmaceutical formulationInfo
- Publication number
- SG11201909062WA SG11201909062WA SG11201909062WA SG11201909062WA SG 11201909062W A SG11201909062W A SG 11201909062WA SG 11201909062W A SG11201909062W A SG 11201909062WA SG 11201909062W A SG11201909062W A SG 11201909062WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- pharmaceutical formulation
- strasse
- english
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 235000015244 frankfurter Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT ill 1111u°11101VIIIVIIIVIIIolo How im olli mutis (10) International Publication Number WO 2018/178134 Al (51) International Patent Classification: CO7D 413/14 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/057877 (22) International Filing Date: 28 March 2018 (28.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17163830.7 30 March 2017 (30.03.2017) EP (71) Applicant: MERCK PATENT GMBH [DE/DE]; Frank- furter Strasse 250, 64293 Darmstadt (DE). (72) Inventors: GEISSLER, Simon; Homburger Strasse 56, 61352 BAD HOMBURG (DE). JESCHKE, Martina; Auf dem Berg 6, 64846 GROSS-ZIMMERN (DE). BONIFORTE, Patrizia; Am Katharinenberg 6a, 64665 ALSBACH-HAEHNLEIN (DE). WEIGANDT, Markus; Trollblumenweg 22, 68259 MANNHEIM (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) 71' 00 N Cit (54) Title: PHARMACEUTICAL FORMULATION 1-1 0 (57) : The present invention relates to a pharmaceutical formulation of (S)-[2-chloro-4-fluoro- -(7-morpholin-4-ylquina- \" zolin-4-yl)pheny1]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof, as well as a method of making 0 same, as well as medical uses thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163830 | 2017-03-30 | ||
| PCT/EP2018/057877 WO2018178134A1 (en) | 2017-03-30 | 2018-03-28 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909062WA true SG11201909062WA (en) | 2019-10-30 |
Family
ID=58461174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909062W SG11201909062WA (en) | 2017-03-30 | 2018-03-28 | Pharmaceutical formulation |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11559490B2 (en) |
| EP (2) | EP4286007A3 (en) |
| JP (1) | JP7228524B2 (en) |
| KR (1) | KR20190130017A (en) |
| CN (1) | CN110446707B (en) |
| AU (1) | AU2018246258B2 (en) |
| BR (1) | BR112019020269A2 (en) |
| CA (1) | CA3058286A1 (en) |
| DK (1) | DK3601277T3 (en) |
| FI (1) | FI3601277T3 (en) |
| HR (1) | HRP20231748T1 (en) |
| HU (1) | HUE064474T2 (en) |
| IL (2) | IL301979B1 (en) |
| LT (1) | LT3601277T (en) |
| MX (1) | MX2019011639A (en) |
| PT (1) | PT3601277T (en) |
| RS (1) | RS65052B1 (en) |
| SG (1) | SG11201909062WA (en) |
| SI (1) | SI3601277T1 (en) |
| TW (2) | TWI808077B (en) |
| WO (1) | WO2018178134A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102013008118A1 (en) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| EP3992189A4 (en) * | 2019-06-27 | 2022-12-07 | Medshine Discovery Inc. | Quinazoline and cinnoline derivatives as dna-pk inhibitor |
| WO2022058323A1 (en) | 2020-09-18 | 2022-03-24 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009087410A2 (en) | 2008-01-11 | 2009-07-16 | Cipla Limited | Solid pharmaceutical dosage form |
| EP2105130A1 (en) * | 2008-03-25 | 2009-09-30 | Ratiopharm GmbH | Pharmaceutical formula and method for its production |
| IN2011CH01887A (en) | 2011-06-02 | 2012-12-14 | ||
| SG11201401459YA (en) * | 2011-10-14 | 2014-07-30 | Array Biopharma Inc | Solid dispersions of a erb2 (her2) inhibitor |
| US20160000720A1 (en) * | 2013-02-14 | 2016-01-07 | Aurobindo Pharma Limited | Pharmaceutical compositions comprising Tadalafil |
| DE102013008118A1 (en) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| EP2913048A1 (en) | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
| JP6203702B2 (en) | 2014-11-18 | 2017-09-27 | 信越化学工業株式会社 | Solution for spray drying using hypromellose acetate succinate and method for producing solid dispersion |
-
2018
- 2018-03-28 EP EP23202392.9A patent/EP4286007A3/en active Pending
- 2018-03-28 KR KR1020197032000A patent/KR20190130017A/en not_active Application Discontinuation
- 2018-03-28 CN CN201880022126.5A patent/CN110446707B/en active Active
- 2018-03-28 RS RS20240029A patent/RS65052B1/en unknown
- 2018-03-28 MX MX2019011639A patent/MX2019011639A/en unknown
- 2018-03-28 JP JP2019553415A patent/JP7228524B2/en active Active
- 2018-03-28 FI FIEP18715593.2T patent/FI3601277T3/en active
- 2018-03-28 WO PCT/EP2018/057877 patent/WO2018178134A1/en active Application Filing
- 2018-03-28 HU HUE18715593A patent/HUE064474T2/en unknown
- 2018-03-28 AU AU2018246258A patent/AU2018246258B2/en active Active
- 2018-03-28 IL IL301979A patent/IL301979B1/en unknown
- 2018-03-28 DK DK18715593.2T patent/DK3601277T3/en active
- 2018-03-28 HR HRP20231748TT patent/HRP20231748T1/en unknown
- 2018-03-28 LT LTEPPCT/EP2018/057877T patent/LT3601277T/en unknown
- 2018-03-28 SI SI201831045T patent/SI3601277T1/en unknown
- 2018-03-28 BR BR112019020269A patent/BR112019020269A2/en active Search and Examination
- 2018-03-28 EP EP18715593.2A patent/EP3601277B1/en active Active
- 2018-03-28 PT PT187155932T patent/PT3601277T/en unknown
- 2018-03-28 CA CA3058286A patent/CA3058286A1/en active Pending
- 2018-03-28 SG SG11201909062W patent/SG11201909062WA/en unknown
- 2018-03-28 US US16/498,943 patent/US11559490B2/en active Active
- 2018-03-28 IL IL269668A patent/IL269668B2/en unknown
- 2018-03-30 TW TW107111175A patent/TWI808077B/en active
- 2018-03-30 TW TW112122367A patent/TW202402297A/en unknown
-
2022
- 2022-12-01 US US18/060,929 patent/US20230119567A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201809671PA (en) | Imidazolone compounds as human neutrophil elastase inhibitors |